Aerovate Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AVTE Nasdaq 2830 aerovatetx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aerovate Therapeutics, Inc.

Jade, another biotech spinout of Paragon, to merge with Aerovate - Oct 31st, 2024 12:18 pm
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement - Oct 31st, 2024 11:00 am
Aerovate Therapeutics to Explore Strategic Alternatives - Jul 8th, 2024 12:00 pm
Ligand to buy Apeiron; Roche reports another TIGIT setback - Jul 8th, 2024 12:00 pm
Aerovate slashes workforce after failed Phase IIb trial - Jul 2nd, 2024 5:13 pm
The 3 Hottest Stock Downgrades From Last Week - Jun 27th, 2024 11:00 am
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals - Jun 18th, 2024 1:21 pm
Why 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke - Jun 17th, 2024 8:04 pm
Top Midday Decliners - Jun 17th, 2024 6:31 pm
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension - Jun 17th, 2024 12:32 pm
Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation - Jun 6th, 2024 2:28 pm
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference - May 21st, 2024 8:15 pm
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights - May 13th, 2024 8:30 pm
Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares - Apr 4th, 2024 5:31 am
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference - Mar 27th, 2024 1:20 pm
Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023 - Mar 27th, 2024 1:01 am
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights - Mar 25th, 2024 8:10 pm
Chief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE) - Mar 21st, 2024 6:32 am
Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ... - Mar 21st, 2024 6:32 am